Document is current
Any future updates will be listed below
-
Authors
Kim, Mijin https://orcid.org/0000-0002-7781-9466
Chen, Chen https://orcid.org/0000-0002-4803-0183
Yaari, Zvi
Frederiksen, Rune
Randall, Ewelina
Wollowitz, Jaina
Cupo, Christian
Wu, Xiaojian
Shah, Janki
Worroll, Daniel
Lagenbacher, Rachel E.
Goerzen, Dana https://orcid.org/0000-0001-9645-3503
Li, Yue-Ming https://orcid.org/0000-0002-2633-3730
An, Heeseon https://orcid.org/0000-0002-8518-4077
Wang, YuHuang
Heller, Daniel A. https://orcid.org/0000-0002-6866-0000
-
Funding
Funding for this research was provided by:
National Science Foundation (1752506, CHE-1904488, CHE-2204202)
Ara Parseghian Medical Research Foundation
Honorable Tina Brozman Foundation
Pershing Square Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30-CA008748)
U.S. Department of Health & Human Services | National Institutes of Health (DP2-HD075698, K99-EB033580, T32-GM136640-Tan, T32-GM141949, T32-CA062948, P30-CA008748, P30-CA008748)
Ovarian Cancer Research Fund Alliance (CRDGAI-2023-3-1003)
Ovarian Cancer Research Fund
Alfred Benzon Foundation
JPB Foundation
- License Information
-
More Information
Article History
Received: 5 August 2022
Accepted: 12 May 2023
First Online: 15 June 2023
Competing interests
: D.A.H. is a cofounder and officer with equity interest in Lime Therapeutics, Inc., cofounder with equity interest in Selectin Therapeutics Inc. and Resident Diagnostics, Inc., and a member of the scientific advisory board of Concarlo Therapeutics, Inc., Nanorobotics Inc. and Mediphage Bioceuticals, Inc. The remaining authors declare no competing interests.
